Glaucoma Therapeutics Market Size Projected to Reach USD 13.5 Billion by 2031, With 5.5% CAGR:

The global glaucoma therapeutics market was projected to attain US$ 8.3 billion in 2022. It is anticipated to garner a 5.5% CAGR from 2023 to 2031 and by 2031, the market is likely to attain US$ 13.5 billion by 2031.

Increases in glaucoma cases, which are a major cause of permanent blindness, are driving the global market for glaucoma therapeutics. Aging populations and increased awareness and early diagnosis support market expansion. Demand is also fueled by new treatment alternatives such as prostaglandin analogs, and combination medicines, as well as technological developments in diagnostic technologies.

Grab Sample of this Research Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16406

Current research and development endeavors concentrate on innovative medications and distribution methods, promoting market growth. The market is still being driven by the search for efficient ways to control intraocular pressure, which is a major component in the development of glaucoma.

Key Findings of Market Report

It is common for diabetics to get glaucoma. Glaucoma risk can be raised by diabetic retinopathy, the most prevalent kind of diabetic eye disease and a consequence of diabetes.

In the United States, diabetes affects around 29 million individuals. The small blood vessels in the retina are harmed by retinopathy.

About 7.7 million Americans who are 40 years of age or older are impacted by it.
The National Diabetes Statistics Report for 2022 from the Centers for Disease Control states that 37.3 million Americans have diabetes.

Providers in the global therapeutics market are carrying out carefully planned and exacting clinical studies to prove the security and effectiveness of their medications.

Market Trends for Glaucoma Therapeutics

In 2022, the hospital end-user category accounted for the majority of share. Since therapy at hospitals is less expensive than at specialist clinics, a considerable portion of the public prefers to receive treatment there first. Hospitals provide sophisticated diagnostic equipment and methods for tracking intraocular pressure and other glaucoma-related factors. This aids in the efficient and focused therapy of the disease.

Current glaucoma drugs work by increasing the outflow of aqueous humor, which lowers intraocular pressure. A more recent type of drug called netarsudil lowers intraocular pressure and increases aqueous fluid outflow. The United States Food and Drug Administration granted Alembic Pharmaceuticals final clearance in March 2023 for its shortened new drug application for Brimonidine Tartrate Ophthalmic Solution, 0.15%.

Patients with open-angle glaucoma or ocular hypertension may benefit from using this medication to lower their excessive intraocular pressure.

Customize this report according to your needs@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=16406

Global Market for Glaucoma Therapeutics: Regional Outlook

Various reasons are propelling the growth of the glaucoma therapeutics market throughout the region. These are:

In 2022, North America held the majority of the share, with Europe following closely behind. The regional market dynamics are being driven by a growth in glaucoma awareness and an aging population. The Glaucoma Research Foundation estimates that three million Americans suffer from glaucoma.
Glaucoma in older persons is six times more common beyond the age of 60. The prevalence of a well-established healthcare infrastructure and the availability of reimbursements are contributing to the increased demand for glaucoma therapies in North America.

Asia Pacific market is anticipated to grow at a rapid rate of growth throughout the projection period. The regional glaucoma treatments market statistics are driven by an increase in the prevalence of glaucoma.

In Jiangxi, China, a cross-sectional research titled "The Prevalence of Glaucoma and Its Related Factors in Rural Residents" found that 1.4% of the 5385 participants had glaucoma. Factors as such are anticipated to push the market during the forecast period.

Global Glaucoma Therapeutics Market: Key Players

To enhance their market position in glaucoma therapeutics and diversify their product offerings, significant businesses are making substantial investments in research and development. The following companies are well-known participants in the global glaucoma therapeutics market:

AbbVie Inc.
Merck & Co. Inc.
Pfizer Inc.
Novartis AG
Santen Pharmaceutical Co. Ltd.
Bausch Health Companies Inc.
Alcon

Some key developments by the players in this market are:

Global Glaucoma Therapeutics Market Segmentation

Drug Class

Prostaglandins
Beta Blockers
Alpha Agonists
Carbonic Anhydrase Inhibitors
Combination Medications
Cholinergic
End User

Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Region

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Enquire Before Buying@ https://www.transparencymarketresearch.com/checkout.php?rep_id=16406<ype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Alani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.